ShineOCT Makes Overseas Debut at Rome International OCT Symposium, Pioneering Global Expansion of China's High-End Ophthalmic Equipment

In recent years,In ChinaMedical Device Exports Surge Sharply. WithThe encouragement of national policies and the development of high-end medical device technology in China,Chinese brands represented by IntalightManufacturerCorrectActiveLayoutOverseas Expansion and Global Development。

December 11, 2022, lasting for 4 days2022 10th International OCT Conference in RomeSuccessfully concluded. At this annual world-class retina academic conference,Intalight Founder and Chairman Dr. Peng Xianzhao Invited to Share Cutting-edge OCT Technology, the RuYi Full-eye OCT Integrating Anterior and Posterior Segment OCT, Anterior and Posterior Segment OCTA, and Whole Axial Visualization Biometry Makes Its Overseas Debut at This Conference, the core technology of Intalight's self-developed OCT surpasses imported products, making a stunning appearance on the world stage. Its wider, deeper, and more refined ultimate imaging won praise from many international experts present.

Intalight Founder and Chairman Dr. Peng Xianzhao Invited to Share OCT Cutting-Edge Technology

The International Rome OCT Conference was first held in 2013 and, after years of development, has now becomeGlobal Showcase of Cutting-Edge OCT/OCTA TechnologiesIndustryThe Most Influential International EventThis year, up to 2,500 experts from within the industry attended the conference, including many authoritative ophthalmology experts from around the world. Intalight, the leader in high-end domestically produced ophthalmic equipment, participated in the conference and promoted its newly upgraded swept-source OCT technology.The implementation of a global strategy and the layout of overseas markets represent a significant move. It also signifies that China-produced advanced technologies and products have begun to "reverse output" beyond its borders and will occupy an advantageous position in the international market.

Group Photo of the 2022 Rome International OCT Conference

According to the introduction,Intalight was founded in 2014 in Silicon Valley by three Chinese-American PhDs.Optical System Expert Peng XianzhaoDr. andDr. Li Bing, Medical Imaging Algorithm ExpertWorld-Class R&D Team Led By, dedicated to integrating cutting-edge optical design, imaging algorithms, artificial intelligence, cloud platforms, and other frontier technologies to provide advanced ophthalmic diagnostic and treatment products for global users. It now ownsSilicon Valley R&D and Operations Center, Shanghai R&D and Operations Center, Luoyang R&D and Manufacturing Center, and plans to establish a European R&D and Operations Center in Germany.

The second half of 2022,Pre-OptovueCompanyJoseph Garibaldi, Global Vice President of Business, has officially joined Intalight as the Chief Commercial Officer (CCO) of the United States, responsible for leading the operations center of Intalight in Silicon Valley, USA.Promote the rapid development of Intalight's series of products in the U.S. market. This means Intalight is accelerating its global layout, helping to advance the internationalization process of high-end ophthalmic equipment produced in China.

Intalight Founder and Chairman Dr. Peng Xianzhao (right) with U.S. CCO Joseph Garibaldi (left)

Data shows that Optovue is a world-leading OCT and OCTA R&D company and a global pioneer in ophthalmic diagnostic equipment. During Joseph's tenure, he facilitated the successful commercialization of the world’s first OCT angiography system, Avanti-AngioVue, and led multiple product lines from inception to maturity. He is an exceptional professional with expertise in the marketing and promotion of advanced ophthalmic devices.

"A good technical product must truly meet market needs and withstand market scrutiny."American doctors have given very positive feedback on the Intalight Full-Eye OCT, and they are thrilled by the capabilities this product can achieve."At present, I am pushing forward the review and approval of Intalight's OCT product in the U.S., and the product is expected to receive FDA certification soon." Joseph told VCBeat. Currently,Ophthalmology experts from Stanford University and other well-known U.S. universities and research institutions have begun to pay attention to and plan to use Intalight OCT for cutting-edge academic research. Collaborations with several world-top ophthalmology experts have been reached, and in the next three months, they will jointly carry out scientific research projects in different professional fields.

Relying on more than 10 years of experience in promoting OCT equipment, under Joseph's leadership,Intalight is making continuous efforts in product certification, academic exchange, scientific research cooperation, and brand promotion in overseas markets such as the United States.To accelerate the layout of the overseas market, Intalight continues to expand its team of overseas elite talents.

For a long time, in the field of high-end ophthalmic equipment, due to the existence of high technical barriers, the domestic market has been occupied by imported products. In recent years, Intalight, as a representative of innovative Chinese manufacturers, is changing this situation.

Since its establishment, Intalight has been focusing on technological innovation in the field of ophthalmic OCT.In 2019, Intalight launched the first swept-source OCT in China to receive NMPA certification.，Breaking the long-term monopoly of imports and solving various "chokepoint" technical problems.

In 2021, Intalight's swept-source OCT received national evaluation of scientific and technological achievements, as appraised by multiple experts in the field:Reach international advanced level comprehensively, which is superior to similar products at home and abroad in terms of speed, breadth, depth, algorithms, and more. This has set a precedent for domestically produced high-end ophthalmic equipment surpassing imported products. Subsequently, leveraging its "hardcore" advantage of integrated software and hardware, Intalight's products continue to undergo relentless research, development, and technological iteration.

In 2022, Intalight globally launched the all-new Ruyi Full-Eye OCT.Can integrate the five cutting-edge functions of anterior segment OCT, anterior segment OCTA, posterior segment OCT, posterior segment OCTA, and full-eye axial visualization biometry on a single device. Each function reaches a world-leading level, ushering in a new era of full-eye OCT and marking a milestone development in the field of swept-source OCT technology as well as high-end domestically produced ophthalmic equipment.

In the global market, Intalight's All-Eye OCT also has significant advantages. Joseph, who has more than 10 years of experience in OCT equipment sales, said: "Intalight's All-Eye OCTHelps doctors make faster and more accurate diagnoses, and can be multi-functional, capturing high-quality anterior and posterior OCT and OCTA images.For many years, ophthalmologists have hoped to perform biometry within OCT devices, and Intalight's Full-Eye OCT has achieved this. It is the first OCT device capable of providing all these functions, which is absolutely astonishing!In the global market outside of China, there are currently almost no OCTA products over 200 degrees commercially available. Intalight's full-eye OCT will fill this market gap!”

Based on the disruptive breakthroughs and continuous innovation upgrades in OCT technology, as well as its world-leading OCT products, Intalight is spearheading the rapid development of high-end ophthalmic devices produced in China, having already mastered the technical capabilities for the global layout of OCT products.

With the innovative and quality advantages of Intalight's full-eye OCT, the device has achieved widespread application in China and gained dual recognition from hospitals at all levels and numerous experts across the country. According to a survey by VCBeat's重磅发布的《2022 Ophthalmology Industry Report》, in 2021,In China, the ultra-high-end OCT market with over 2 million units, Intalight's swept-source OCT has achieved a market share of 42%, surpassing imported brands to rank first.

As of now, Intalight OCTSales have broken through 130 units., among whichExceed50PlatformIntalight OCT has been introduced into leading ophthalmic centers across China or benchmark hospitals in various provinces, with many hospitals making continuous repeat purchases. Intalight OCT has now become a powerful tool for clinical doctors at numerous top-tier tertiary hospitals in China to advance their research and has already assisted domestic experts in publishing64 articlesInternational Journal SCI Article.

Intalight Full-Eye OCT Illuminates China

Based on its tremendous clinical and research value, Intalight OCT has garnered numerous top-tier honors and accolades in China, such as being named one of the "Top Ten Advances in Chinese Ophthalmology in 2021," listed in the Eighth Edition of the Directory of Outstanding Medical Device Products, awarded the "Ophthalmology Science and Technology Progress Award" and the "Outstanding Industry Contribution Award," winning first place at the 2022 World Ophthalmology Forum Roadshow Competition, and most recently, being recognized as one of the "Top 100 Most Innovative Medical Technology Products of 2022"…

According to Dr. Li Bing, CEO of Intalight,This sales achievement holds a notably leading position among similar products both in China and internationally.In the past three years, despite the impact of the pandemic, sales performance has still grown against the trend and is now achieving stable profitability. With a top-notch R&D team, excellent product performance, rapidly increasing market share, and steady financial results, Intalight has attracted investments from multiple venture capital institutions and receivedAier Medical, the leading company in the ophthalmology services fieldStrategic Investment.

Based on its own high-end OCT equipment productization and mass production experience,Intalight is transitioning from the previous entrepreneurial phase 1.0 toBrand enhancement, product expansion,The 2.0 Era of Globalization Layout,A series of strategic initiatives in the core European and American markets, along with the recruitment of global talent, have laid a solid foundation for its global layout, while the clinical advantages of its products and technological innovation capabilities will help it quickly break through overseas markets.

Intalight's Global Layout

Dr. Peng Xianzhao, founder and chairman of Intalight, stated that under the recent wave of import substitution, Intalight's swept-source OCT is disrupting the high-end ophthalmic device market in China with its strong technological innovation, greatly promoting the localization of products in this cutting-edge technology field. Technological innovation knows no borders.We are very pleased to bring this excellent domestically developed product to the U.S. and global markets. Intalight's latest full-eye OCT, Ruyi, will provide ophthalmologists worldwide with an unprecedented, one-stop examination solution applicable to all ophthalmic scenarios.

Intalight's U.S. CCO Joseph expressed great confidence in the development of Intalight's OCT in overseas markets: "Intalight’s sales in China are currently very strong and show tremendous potential for continued growth in the coming years, becoming one of the best-selling ophthalmic OCT devices in China. With the multi-faceted advantages of the Ruyi Full-Eye OCT, we believe it will carve out an even broader space in the U.S. and global markets in the future."

Since its establishment, Intalight has focused on and deeply cultivated the swept-source OCT technology field. Over time, Intalight has now built an elite team that integrates technology research and development, clinical application and product design, market sales and technical services, and lean production. It has established a quality control system for mass production, and completed the construction of the supply chain and sales network.

Drawing on the successful experience of swept-source OCT,Relying on a world-class R&D team with over 20 years of Silicon Valley engineering experience, semiconductor optics, and high-end medical device development expertise, in addition to its OCT products, Intalight is comprehensively expanding into the field of advanced ophthalmic diagnostic and treatment equipment for global ophthalmology users.

In the field of ophthalmic diagnosis, Intalight will launch a solution for fundus diseases.AI-Assisted Diagnosis Technology, fully upgrading the functional boundaries of Intalight OCT, while the upcoming launch ofNext-Generation Swept-Source Biometer, the detection rate of cataracts has been increased to over 99%, thereby solving the problem of insufficient detection rates in existing market products; Intalight plans to launchChina's First Ultra-Widefield True Color Fundus Camera, surpassing existing foreign brand products in both the "wide-angle" and "true color" dimensions.

In the field of ophthalmic treatment, Intalight will integrate the latest OCT technology to launchIntalight OCT Navigation Surgical Microscope.Relying on the R&D experience of semiconductor optical equipment possessed by Intalight's R&D team, Intalight willBuild a globally leading all-femtosecond refractive surgery system, truly achieving the accumulation of key core technologies in the full femtosecond field, fundamentally breaking the monopoly of foreign brands, and further enhancing the safety, convenience, and applicability of full femtosecond refractive surgery.

"The original intention of Intalight's global layout is to bring China-produced, self-developed advanced technology products to the world, serving users globally. Our goal is..."Becoming the Chinese Representative in the Global High-End Ophthalmic Device Market"!" said Dr. Peng Xianzhao, founder and chairman of Intalight. Currently, the company is accelerating the research and development of different ophthalmic product lines, and plans to launch more core technology products that are "Made in China" and world-leading in the future, with the aim of promoting the development of global eye health!